Abstract: A closed-loop neuromodulation system includes at least one implantable neurostimulator configured to deliver electrical stimulation to a target nerve innervating a muscle; at least one biosignal sensor configured to detect a physiological signal associated with the target muscle, wherein the physiological signal may include an electromyographic (EMG) or electroneurographic (ENG) signal; and a controller operatively coupled to the neurostimulator and the sensor. The controller is configured to receive the physiological signal from the sensor, determine whether the signal satisfies a predefined condition indicative of weakness, strength, fatigue, muscle underactivity, or overstimulation, and, in response to detecting that the condition is satisfied, automatically adjust one or more stimulation parameters selected from amplitude, frequency, pulse width, train duration, or train count.

Abstract: A neuromodulation device includes a movable arm coupled with a main body. The movable arm is configured to transition between an open configuration and a closed configuration. The movable arm is biased towards the closed configuration. A nerve stimulation chamber is defined at least in part by the movable arm. The nerve stimulation chamber is configured to retain a nerve therein. The device has an open channel through which the nerve travels. The channel is defined at least in part by the movable arm. The size and shape of the chamber and the channel are adjustable by the movement of the arm in response to contact with the nerve. The channel may be continuously axial along a longitudinal axis of the channel when the movable arm is in the closed configuration. The chamber has an electrode.

Abstract: A method stimulates a nerve by providing a device having an arm formed of an elastomeric material. A channel through which the nerve travels is defined at least in part by the arm. The channel has a continuously axial longitudinal axis at rest. A nerve stimulation chamber is defined at least in part by the arm. The nerve stimulation chamber is configured to retain the nerve therein. The device has an electrode in the chamber. The method reduces a dimension of a nerve. The is less than 50% of the diameter of the undeformed nerve. The device is configured to apply less than 6.7 kPa of pressure to the nerve at any given point. The nerve is positioned in the chamber, and the cross-sectional dimension of the stretched nerve is increased. At least 20% of the perimeter of the nerve is maintained in contact with the electrode.

Abstract: A nerve regeneration system includes a nerve guide having a proximal end and a distal end. The system includes nerve growth factor configured to enhance the growth of axons and associated nerve tissue. The nerve growth factor has a first concentration nearer to a proximal end and a second growth factor concentration nearer to a distal end. The second growth factor concentration is higher than the first growth factor concentration. The system includes myelination factor configured to enhance myelination of the grown axons. The myelination factor has a first myelination factor concentration nearer to the proximal end, a third myelination factor concentration nearer to the distal end, and a second myelination factor concentration between the first myelination factor concentration and the third myelination factor concentration. The second myelination factor concentration is higher than the first myelination factor and higher than the third myelination factor concentration.

Abstract: A method and/or system controls bladder function of a patient having a symptom related to overactive bladder (OAB) or stress unitary incontinence (SUI). The symptom related to OAB is produced by a natural OAB signal generated by the patient's body. To that end, the method couples an electrode to a prescribed somatic motor nerve (e.g., the perineal nerve) associated with the pelvic floor, and then transmits, via the electrode, an OAB control signal to the prescribed somatic motor nerve. The OAB control signal is configured to activate the pelvic floor in a prescribed manner to mitigate the effect of the natural OAB signal on the pelvic floor.

Abstract: In a first embodiment, an ultrasound energy delivery assembly includes a waveguide and a catheter having a capture member. The capture member extends radially inward from an interior surface of the catheter into a lumen of the catheter and is configured to retain the enlarged distal tip so that the enlarged distal tip is temporarily prevented from moving proximally. In a second embodiment, an ultrasound energy delivery assembly includes a waveguide and a sheath covering at least a portion of the waveguide. In a third embodiment, an ultrasound energy delivery assembly includes a waveguide and a dual lumen catheter having a capture member. In a fourth embodiment, an ultrasound energy delivery assembly includes a waveguide and a catheter having a proximal waveguide lumen and a proximal guide wire lumen that merges with the proximal waveguide lumen at their respective distal ends to form a distal lumen.